Fig. 1From: Development of molecular and pharmacological switches for chimeric antigen receptor T cellsDasatinib, a tyrosine kinase inhibitor against BCR-ABL, can inhibit the phosphorylation and activation of components in the T cell receptor signaling pathways. It was shown to be effective in reversing CD19-CAR-T cell mediated cytokine release syndrome in a recently published preclinical model [8]Back to article page